Acadia Pharmaceuticals is scheduled to resume trading at 4:35 pm ET, with quotation set to resume at 4:30 pm ET, according to Nasdaq. Shares had been halted, news pending, as the company announced that its phase 3 Pimavanserin study in negative symptoms of Schizophrenia did not meet its primary endpoint.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACAD:
- Acadia Pharmaceuticals should be bought on weakness, says Mizuho
- Australian Stocks: Neuren’s (NEU) Daybue Sales Fail to Impress, Shares Plunge
- Acadia Pharmaceuticals provides FY24 product sales guidance
- Acadia Pharmaceuticals reports Q4 EPS 28c, consensus 30c
- ACADIA Pharmaceuticals Inc. (ACAD) Q4 Earnings Cheat Sheet
